Evaluation of diffusion-weighted magnetic resonance imaging and contrast-enhanced harmonic ultrasonography in detection and location of prostate transition-zone cancer

Journal of International Medical Research

Volumn 39, Issue 1, 2011, Pages 256-266

  Wang, R ^a   Chen, J J ^b   Zhou, Y C ^a   Huang, M M ^a   Zhang, X R ^a   Miao, H D ^c  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b SHANGHAI CHILDREN S HOSPITAL   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Contrast enhanced hremonic ultrasonography; Diffusion weighted magnetic resonance imaging; Prostate cancer; Transition zone

Indexed keywords

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; ECHOGRAPHY; HUMAN; HUMAN TISSUE; INSTRUMENT VALIDATION; INTERMETHOD COMPARISON; MALE; PREDICTIVE VALUE; PROSTATE CANCER; PROSTATECTOMY; SENSITIVITY AND SPECIFICITY;

EID: 79952978720     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001103900128     Document Type: Article

References (54)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al: Cancer statistics, 2001. CA Cancer J Clin 2001; 51: 15-36.
2. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30.
3. Shao C-X, Xiang Y-B, Liu Z-W, et al: The analysis of the relative survival for urological cancer in urban Shanghai. Chin J Clin Oncol 2005; 32: 321-327.
4. Halpern EJ, Strup SE: Using gray-scale and color and power Doppler sonography to detect prostatic cancer. AJR Am J Roentgenol 2000; 174: 623-627.
5. Hodge KK, McNeal JE, Terris MK, et al: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142: 71-75.
6. Damiano R, Autorino R, Perdona S, et al: Are extended biopsies really necessary to improve prostate cancer detection? Prostate Cancer Prostatic Dis 2003; 6: 250-255.
7. Bourdin S, Karam G, Clemain P, et al: Clinical experience with leuprorelin acetate before radiotherapy for prostatic cancer. J Int Med Res 1990; 18(suppl 1): 74-78.
8. Eskew LA, Bare RL, McCullough DL: Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-203.
9. McNeal JE, Redwine EA, Freiha FS, et al: Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12: 897-906.
10. Noguchi M, Stamey TA, Neal JE, et al: An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics. J Urol 2000; 163: 1751-1755.
11. Sakai I, Harada K, Kurahashi T, et al: Analysis of differences in clinicopathological features between prostate cancers located in the transition and peripheral zones. Int J Urol 2006; 13: 368-372.
12. Augustin H, Hammerer PG, Blonski J, et al: Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy? Urology 2003; 62: 79-85.
13. Yunkai Z, Yaqing C, Ren W, et al: Are transition zone biopsies necessary in transrectal ultrasound-guided transperineal prostate biopsy protocol? Results of a Chinese population-based study. Clin Imaging 2010: 34: 43-46.
14. Stewart CS, Leibovich BC, Weaver AL, et al: Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies. J Urol 2001; 166: 86-92.
15. Rabbani F, Sullivan LD: Transition zone carcinoma of the prostate. Can J Urol 1995; 2: 189-191.
16. Czerwinskyj C, Rifkin MD: Efficacy of including the transition zone in routine biopsies of the prostate in men at high risk. Ultrasound Q 2001; 17: 181-184.
17. Seitz M, Gratzke C, Schlenker B, et al: Contrast- enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer. Urol Oncol 2009; epub ahead of print.
18. Aigner F, Pallwein L, Mitterberger M, et al: Contrast-enhanced ultrasonography using cadence-contrast pulse sequencing technology for targeted biopsy of the prostate. BJU Int 2009; 103: 458-463.
19. Heijmink SW, Barentsz JO: Contrast-enhanced versus systematic transrectal ultrasound-guided prostate cancer detection: an overview of techniques and a systematic review. Eur J Radiol 2007; 63: 310-316.
20. Mitterberger M, Horninger W, Pelzer A, et al: A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection. Prostate 2007; 67: 1537-1542.
21. Pelzer A, Bektic J, Berger AP, et al: Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy. J Urol 2005; 173: 1926-1929.
22. Dickinson L, Ahmed HU, Moore C, et al: The effects of the time period between biopsy and diffusion-weighted magnetic resonance imaging on cancer staging in localized prostate cancer. BJU Int 2010; 106: 131-132.
23. Woodfield CA, Tung GA, Grand DJ, et al: Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 2010; 194: W316-W322.
24. deSouza NM, Riches SF, Vanas NJ, et al: Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol 2008; 63: 774-782.
25. Haider MA, van der Kwast TH, Tanguay J, et al: Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol 2007; 189: 323-328.
26. Morgan VA, Kyriazi S, Ashley SE, et al: Evaluation of the potential of diffusion- weighted imaging in prostate cancer detection. Acta Radiol 2007; 48: 695-703.
27. Hosseinzadeh K, Schwarz SD: Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging 2004; 20: 654-661.
28. Gunelli R, Fiori M, Bercovich E: Imaging of the prostate: traditional methods. Arch Ital Urol Androl 2002; 74: 177-181 [in Italian, English abstract].
29. Issa B: In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging. J Magn Reson Imaging 2002; 16: 196-200.
30. Sato C, Naganawa S, Nakamura T, et al: Differentiation of noncancerous tissue and cancer lesions by apparent diffusion coefficient values in transition and peripheral zones of the prostate. J Magn Reson Imaging 2005; 21: 258-262.
31. Shimofusa R, Fujimoto H, Akamata H, et al: Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr 2005; 29: 149-153.
32. Song SK, Qu Z, Garabedian EM, et al: Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model. Cancer Res 2002; 62: 1555-1558.
33. Goldberg BB, Liu JB, Forsberg F: Ultrasound contrast agents: a review. Ultrasound Med Biol 1994; 20: 319-333.
34. Halpern EJ: Contrast-enhanced ultrasound imaging of prostate cancer. Rev Urol 2006; 8 (suppl 1): S29-S37.
35. Ko EY, Lee SH, Kim HH, et al: Evaluation of tumor angiogenesis with a second-generation US contrast medium in a rat breast tumor model. Korean J Radiol 2008; 9: 243-249.
36. Lee SH, Suh JS, Shin MJ, et al: Quantitative assessment of synovial vascularity using contrast-enhanced power Doppler ultrasonography: correlation with histologic findings and MR imaging findings in arthritic rabbit knee model. Korean J Radiol 2008; 9: 45-53.
37. Mitterberger M, Pinggera GM, Horninger W, et al: Comparison of contrast enhanced color Doppler targeted biopsy to conventional systematic biopsy: impact on Gleason score. J Urol 2007; 178: 464-468.
38. Bono AV, Celato N, Cova V, et al: Microvessel density in prostate carcinoma. Prostate Cancer Prostatic Dis 2002; 5: 123-127.
39. Bostwick DG, Wheeler TM, Blute M, et al: Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996; 48: 47-57.
40. Borre M, Offersen BV, Nerstrøm B, et al: Microvessel density predicts survival in prostate cancer patients subjected to watchful waiting. Br J Cancer 1998; 78: 940-944.
41. Goossen TE, de la Rosette JJ, Hulsbergen-van de Kaa CA, et al: The value of dynamic contrast enhanced power Doppler ultrasound imaging in the localization of prostate cancer. Eur Urol 2003; 43: 124-131.
42. Qian J, Wollan P, Bostwick DG: The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol 1997; 28: 143-148.
43. Stamey TA, Donaldson AN, Yemoto CE, et al: Histological and clinical findings in 896 consecutive prostates treated only with radical retropubic prostatectomy: epidemiologic significance of annual changes. J Urol 1998; 160: 2412-2417.
44. Reissigl A, Pointner J, Strasser H, et al: Frequency and clinical significance of transition zone cancer in prostate cancer screening. Prostate 1997; 30: 130-135.
45. Augustin H, Erbersdobler A, Graefen M, et al: Biochemical recurrence following radical prostatectomy: a comparison between prostate cancers located in different anatomical zones. Prostate 2003; 55: 48-54.
46. Erbersdobler A, Augustin H, Schlomm T, et al: Prostate cancers in the transition zone: part 1: pathological aspects. BJU Int 2004; 94: 1221-1225.
47. Augustin H, Erbersdobler A, Hammerer PG, et al: Prostate cancers in the transition zone: part 2: clinical aspects. BJU Int 2004; 94: 1226-1229.
48. Lui PD, Terris MK, McNeal JE, et al: Indications for ultrasound guided transition zone biopsies in the detection of prostate cancer. J Urol 1995; 153: 1000-1003.
49. Jack GS, Cookson MS, Coffey CS, et al: Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. J Urol 2002; 168: 519-524.
50. McNeal JE, Price HM, Redwine EA, et al: Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. J Urol 1988; 139: 61-65.
51. Gelet A, Chapelon JY, Bouvier R, et al: Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 2001; 40: 124-129.
52. Stamey TA, Sozen TS, Yemoto CM, et al: Classification of localized untreated prostate cancer based on 791 men treated only with radical prostatectomy: common ground for therapeutic trials and TNM subgroups. J Urol 1998; 159: 2009-2012.
53. Fleshner NE, Fair WR: Indications for transition zone biopsy in the detection of prostatic carcinoma. J Urol 1997; 157: 556-558.
54. Perrotti M, Han KR, Epstein RE, et al: Prospective evaluation of endorectal magnetic resonance imaging to detect tumor foci in men with prior negative prostatic biopsy: a pilot study. J Urol 1999; 162: 1314-1317.